Continuous Versus Intermittent cARdiac Electrical moNitorinG

Primary outcomes

1. Comparison of blinded, manual measurements of the ECGs to the patch monitor tracings as measured by the Bland-Altman Plot

   Time frame: Through Day 30

   • The Bland Altman plot provides a graphical method to compare the question of interest, namely that the measurements derived from the patch monitor are accurate in relation to the gold standard of the ECG.
   • Each QT measured from the tracing will be plotted against the difference in QT between the tracing and the 12-lead ECG. The acceptable difference between measurement techniques will be set at 5 ms (primary, strict threshold based on FDA recommendations) with a clinically acceptable difference of 15 ms (based on known variability in 12-lead ECG recordings).

2. Frequency of major arrhythmia occurrence

   Time frame: Through Day 30

   • The QT interval will be assessed every 4 hours for the first 5 days and then every 8 hours thereafter

3. Trajectories of QT prolongation

   Time frame: Through day 30

   • Will assess the QT interval every four hours for five days after drug initiation and after five days, the QTc will be assessed every 8 hours
   • With this data, the investigators will plot the QTc interval (Fridericia correction) over time and determine the time of expected peak effect. Outliers will be reviewed and verified manually.